Poonawalla Reaps Riches In Vaccine Rollouts
Cyrus Poonawalla has another passion besides horses and cars — making jabs for the masses.
Cyrus Poonawalla has another passion besides horses and cars — making jabs for the masses.
The stellar run continues post-Covid as promoters reap benefits of growth in India and new launches in key markets.
As per the new arrangement, Biocon Biologics will have access to 100 million doses of vaccines annually together with the distribution rights to Serum Institute’s vaccine portfolio.
Cyrus Soli Poonawalla’s Serum Institute of India made the most of the country’s demand for vaccines.
The owner of world's biggest vaccine maker is also known for his interest in social causes.
While the initial rollout will be for supplies to the government vaccination programme, commercial open sales may begin early 2023, says Adar Poonawalla.
Serum Institute chief executive Adar Poonawalla, during a media event today, said the company has 200 million doses of vaccine stock available currently.
India has learned a lot and is in a stronger and better position to face any future wave or future pandemics, says Adar Poonawalla.
Covid-19 vaccines Corbevax and Covovax, and anti-viral medication Molnupiravir have been granted emergency use authorisation by the CDSCO.
Poonawalla says the biggest learning from the pandemic has been the realisation that one should not make forward looking predictions, as things have been changing fast with Covid-19